- Home
- FENC vs ACHV Comparison
FENC vs ACHV Comparison
Compare FENC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- ACHV
- Stock Information
- Founded
- FENC 1996
- ACHV N/A
- Country
- FENC United States
- ACHV Canada
- Employees
- FENC N/A
- ACHV N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FENC Health Care
- ACHV Health Care
- Exchange
- FENC Nasdaq
- ACHV Nasdaq
- Market Cap
- FENC 156.9M
- ACHV 126.9M
- IPO Year
- FENC 2001
- ACHV N/A
- Fundamental
- Price
- FENC $5.54
- ACHV $3.09
- Analyst Decision
- FENC Strong Buy
- ACHV Strong Buy
- Analyst Count
- FENC 2
- ACHV 5
- Target Price
- FENC $14.00
- ACHV $14.80
- AVG Volume (30 Days)
- FENC 73.5K
- ACHV 277.4K
- Earning Date
- FENC 11-07-2024
- ACHV 11-07-2024
- Dividend Yield
- FENC N/A
- ACHV N/A
- EPS Growth
- FENC N/A
- ACHV N/A
- EPS
- FENC N/A
- ACHV N/A
- Revenue
- FENC $49,348,000.00
- ACHV N/A
- Revenue This Year
- FENC $170.43
- ACHV N/A
- Revenue Next Year
- FENC $6.70
- ACHV N/A
- P/E Ratio
- FENC N/A
- ACHV N/A
- Revenue Growth
- FENC 278.09
- ACHV N/A
- 52 Week Low
- FENC $3.96
- ACHV $3.04
- 52 Week High
- FENC $11.49
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- FENC 40.02
- ACHV 29.72
- Support Level
- FENC $5.61
- ACHV $3.12
- Resistance Level
- FENC $6.19
- ACHV $3.86
- Average True Range (ATR)
- FENC 0.26
- ACHV 0.21
- MACD
- FENC -0.10
- ACHV -0.03
- Stochastic Oscillator
- FENC 6.42
- ACHV 8.33
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.